EUVIMEDEUVIMED entdecken
Leserbrief

Eligibility in a cohort of patients with hidradenitis suppurativa treated with bimekizumab: Lessons and pitfalls in a real‐world setting

C Ureña-Paniego iD, S Haselgruber iD, A Soto-Moreno, C Cuenca-Barrales, S Arias-Santiago, A Molina-Leyva iD

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19921 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von C Ureña-Paniego und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The data that support the findings of this study are not publicly available due to it containing information that could compromise the privacy of research participants but could be available from the corresponding author upon reasonable request.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaHumansMaleFemaleAdultMiddle AgedEligibility DeterminationCohort StudiesRetrospective Studies

Autor:innen und Institutionen

  • Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Hidradenitis Suppurativa Clinic, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
  • European Hidradenitis Suppurativa Foundation, Dessau-Roßlau, Germany.

ORCID-Profile: C Ureña-Paniego, S Haselgruber, A Molina-Leyva

Zitieren

APA

Ureña-Paniego, C., Haselgruber, S., Soto-Moreno, A., Cuenca-Barrales, C., Arias-Santiago, S., & Molina-Leyva, A. (2024). Eligibility in a cohort of patients with hidradenitis suppurativa treated with bimekizumab: Lessons and pitfalls in a real‐world setting. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19921

Vancouver

Ureña-Paniego C, Haselgruber S, Soto-Moreno A, Cuenca-Barrales C, Arias-Santiago S, Molina-Leyva A. Eligibility in a cohort of patients with hidradenitis suppurativa treated with bimekizumab: Lessons and pitfalls in a real‐world setting. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19921

BibTeX
@article{UreaPaniego2024,
  author = {Ureña-Paniego, C and Haselgruber, S and Soto-Moreno, A and Cuenca-Barrales, C and Arias-Santiago, S and Molina-Leyva, A},
  title = {Eligibility in a cohort of patients with hidradenitis suppurativa treated with bimekizumab: Lessons and pitfalls in a real‐world setting},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19921}
}
Kostenlos starten →